The company plans to deliver by next year the order for the IV treatment, which would be a vital option for patients unable to swallow the oral pill as monkeypox symptoms include rashes and blisters in the mouth.
https://www.pharmalive.com/wp-content/uploads/2022/05/U.S.-births-rise-for-the-first-time-in-seven-years-in-2021-Reuters-5-24-22.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-08-09 08:27:052022-08-09 11:51:12U.S. to buy Siga’s IV drug worth $26M to fight monkeypox outbreak
